SABS
SAB Biotherapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-48/100
Last price
2.96
▲ 0.03 (1.02%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
3.20
Prev close
2.93
Day high
2.96
Day low
2.90
Volume
96.20K
Market cap
$269.32M
P/E (TTM)
—
52W range
2.10 – 5.15
Day trading desk
Gap from prior close
+9.22%
Prior close 2.93
VWAP
2.94
+0.66% from price
Relative volume
0.19×
Quiet session
Session range
10.34%
2.90 – 3.20
Position in range
20%
Near session low
ATR (14D)
0.19
6.41% of price
Prior day high
3.16
PDH
Prior day low
2.91
PDL
Bid / ask spread
—
Quote not published
Session volume
95.86K
Avg 495.86K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-6.62%
-8.1%
1M
-18.46%
-19.5%
3M
-25.25%
-28.2%
6M
-20.64%
-35.2%
YTD
-20.86%
-34.4%
1Y
+29.26%
+14.0%
3Y
-55.15%
-136.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SABS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
642.36K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 29, 25 | SESSA CAPITAL MASTER, L.P. Beneficial Owner of more than 10% of a Class of Security |
CONVERSION | 1.74M | $3.04M | Indirect |
| Sep 29, 25 | MOIN ANDREW D. Director |
CONVERSION | 1.74M | $3.04M | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
MOIN ANDREW D. |
Director | — | Conversion of Exercise of derivative security |
SESSA CAPITAL MASTER, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
Fundamentals
Market cap$269.32M
Enterprise value$169.09M
Revenue (TTM)—
Gross profit$-48.27M
EBITDA$-68.71M
Net income$-21.79M
EPS (TTM)$-1.29
Free cash flow$-28.84M
Total cash$102.63M
Total debt$5.13M
Book value / share$2.57
Shares outstanding90.99M
Float62.04M
Short % of float4.09%
Dividend yield0.00%
Beta (5Y)0.58
Valuation & profitability ratios
Trailing P/E—
Forward P/E-3.10
PEG ratio—
Price / sales—
Price / book1.15
EV / revenue—
EV / EBITDA-2.46
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-11.27%
Return on assets-33.46%
Debt / equity2.39
Current ratio9.22
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | — | — |
| Research & development | $34.35M | $30.25M | $16.52M | $36.44M | — | +13.6% |
| Selling, general & admin | $14.60M | $13.98M | $23.80M | $16.38M | — | +4.4% |
| Total operating expense | $48.95M | $42.91M | $38.08M | $28.92M | — | +14.1% |
| Operating income | -$48.95M | -$42.91M | -$38.08M | -$28.92M | — | -14.1% |
| Net interest income | $1.19M | $967.60K | $269.68K | -$230.51K | — | +23.1% |
| Pre-tax income | $13.27M | -$34.11M | -$42.19M | -$18.72M | — | +138.9% |
| Tax provision | — | — | $0 | $25.63K | $0 | — |
| Net income | $13.27M | -$34.11M | -$42.19M | -$18.74M | — | +138.9% |
| Net income to common | $13.27M | -$34.11M | -$42.19M | -$18.74M | — | +138.9% |
| Basic EPS | 0.22 | -3.68 | -7.64 | -4.31 | — | +106.0% |
| Diluted EPS | -0.79 | -3.68 | -7.64 | -4.31 | — | +78.5% |
| EBIT | $13.51M | -$33.79M | -$41.88M | -$18.41M | — | +140.0% |
| EBITDA | $16.60M | -$28.99M | -$38.13M | -$15.12M | — | +157.2% |
| Basic shares | 19.31M | 9.26M | 5.52M | 4.35M | — | +108.5% |
| Diluted shares | 61.34M | 9.26M | 5.52M | 4.35M | — | +562.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $10.50M | $8.90M | $56.57M | $15.05M | — | +18.0% |
| Cash & short-term investments | $96.59M | $20.76M | $56.57M | $15.05M | — | +365.3% |
| Accounts receivable | — | — | $0 | $5.56M | $8.01M | — |
| Total current assets | $101.05M | $23.79M | $58.91M | $22.10M | — | +324.7% |
| Property, plant & equipment | $19.40M | $19.92M | $24.68M | $28.34M | — | -2.6% |
| Total assets | $172.81M | $44.20M | $83.94M | $50.90M | — | +291.0% |
| Total current liabilities | $10.68M | $7.98M | $10.81M | $14.99M | — | +33.9% |
| Current debt | — | $275.85K | $1.05M | $772.66K | $1.80M | — |
| Long-term debt | — | — | — | $541.64K | — | — |
| Total debt | $5.95M | $4.67M | $5.91M | $5.93M | — | +27.5% |
| Total liabilities | $21.32M | $18.23M | $26.64M | $19.85M | — | +17.0% |
| Retained earnings | -$110.90M | -$124.17M | -$90.06M | -$47.87M | — | +10.7% |
| Shareholder equity | $151.49M | $25.97M | $57.30M | $31.06M | — | +483.4% |
| Working capital | $90.37M | $15.81M | $48.09M | $7.10M | — | +471.5% |
| Net tangible assets | $151.49M | $25.97M | $57.30M | $31.06M | — | +483.4% |
| Shares issued | 47.66M | 9.34M | 9.28M | 5.09M | — | +410.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $13.27M | -$34.11M | -$42.19M | -$18.74M | — | +138.9% |
| Depreciation & amortisation | $3.08M | $4.79M | $3.75M | $3.29M | — | -35.7% |
| Stock-based compensation | $5.21M | $2.94M | $2.42M | $2.67M | — | +77.1% |
| Change in working capital | -$3.69M | -$2.30M | $2.33M | -$237.57K | — | -60.3% |
| Operating cash flow | -$44.78M | -$34.29M | -$25.12M | -$23.46M | — | -30.6% |
| Capital expenditure | -$933.16K | -$337.26K | -$197.15K | -$2.17M | — | -176.7% |
| Investing cash flow | -$121.71M | -$11.96M | -$152.70K | -$2.09M | — | -917.4% |
| Share buybacks | — | — | $0 | -$5.52M | $0 | — |
| Financing cash flow | $168.30M | -$1.17M | $66.77M | $1.05M | — | +14,452.4% |
| Free cash flow | -$45.71M | -$34.63M | -$25.32M | -$25.63M | — | -32.0% |
| End cash position | $10.50M | $8.90M | $56.57M | $15.05M | — | +18.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $16.17M | $13.40M | $10.73M | $8.97M | $7.00M | — | +20.7% |
| Selling, general & admin | $7.21M | $6.60M | $5.04M | $3.71M | $2.73M | — | +9.2% |
| Total operating expense | $23.38M | $20.00M | $15.77M | $12.68M | $9.73M | — | +16.9% |
| Operating income | -$23.38M | -$20.00M | -$15.77M | -$12.68M | -$9.73M | — | -16.9% |
| Net interest income | $1.65M | $984.45K | $637.28K | $611.94K | -$50.00K | — | +67.3% |
| Pre-tax income | -$22.49M | -$18.87M | -$16.86M | $45.45M | -$10.11M | — | -19.2% |
| Net income | -$22.49M | -$18.87M | -$16.86M | $45.45M | -$10.11M | — | -19.2% |
| Net income to common | -$22.49M | -$18.87M | -$16.86M | $45.45M | -$10.11M | — | -19.2% |
| Basic EPS | -0.28 | -0.35 | — | 0.50 | -1.09 | -0.56 | +20.0% |
| Diluted EPS | -0.28 | -0.35 | — | -0.21 | -1.09 | -0.56 | +20.0% |
| EBIT | -$22.43M | -$18.81M | -$16.80M | $45.49M | -$10.05M | — | -19.3% |
| EBITDA | -$21.59M | -$18.05M | -$16.03M | $46.26M | -$9.28M | — | -19.6% |
| Basic shares | 79.75M | 53.56M | — | 10.66M | 9.29M | 9.29M | +48.9% |
| Diluted shares | 79.75M | 53.56M | — | 77.86M | 9.29M | 9.29M | +48.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $8.27M | $20.52M | $10.50M | $29.42M | $3.69M | — | -59.7% |
| Cash & short-term investments | $102.63M | $107.39M | $96.59M | $110.88M | $5.71M | — | -4.4% |
| Total current assets | $107.94M | $112.78M | $101.05M | $113.28M | $9.31M | — | -4.3% |
| Property, plant & equipment | $19.58M | $20.17M | $19.40M | $19.44M | $20.40M | — | -2.9% |
| Total assets | $238.21M | $248.47M | $172.81M | $183.45M | $30.13M | — | -4.1% |
| Total current liabilities | $11.71M | $9.85M | $10.68M | $10.79M | $10.68M | — | +18.8% |
| Current debt | — | — | — | — | — | $138.55K | — |
| Total debt | $5.13M | $6.17M | $5.95M | $6.19M | $6.42M | — | -16.9% |
| Total liabilities | $23.43M | $21.22M | $21.32M | $18.37M | $18.11M | — | +10.4% |
| Retained earnings | -$152.25M | -$129.76M | -$110.90M | -$94.03M | -$139.48M | — | -17.3% |
| Shareholder equity | $214.78M | $227.25M | $151.49M | $165.07M | $12.02M | — | -5.5% |
| Working capital | $96.23M | $102.93M | $90.37M | $102.48M | -$1.37M | — | -6.5% |
| Net tangible assets | $214.78M | $227.25M | $151.49M | $165.07M | $12.02M | — | -5.5% |
| Shares issued | 83.49M | 75.80M | 47.66M | 47.55M | 9.35M | — | +10.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$22.49M | -$18.87M | -$16.86M | $45.45M | -$10.11M | -19.2% |
| Depreciation & amortisation | $834.33K | $752.67K | $763.30K | $766.29K | $773.70K | +10.8% |
| Stock-based compensation | $7.25M | $5.46M | $3.17M | $800.91K | $627.05K | +32.7% |
| Change in working capital | $3.24M | -$2.06M | -$7.32M | $1.62M | $942.48K | +257.4% |
| Operating cash flow | -$9.84M | -$14.27M | -$16.78M | -$13.05M | -$7.15M | +31.0% |
| Capital expenditure | -$1.59M | -$983.26K | — | — | — | -61.3% |
| Investing cash flow | -$4.88M | -$65.65M | -$1.71M | -$129.87M | $5.20M | +92.6% |
| Financing cash flow | $2.36M | $89.92M | -$41.69K | $168.69M | -$174.01K | -97.4% |
| Free cash flow | -$11.43M | -$15.25M | -$17.71M | -$13.05M | -$7.15M | +25.1% |
| End cash position | $8.27M | $20.52M | $10.50M | $29.42M | $3.69M | -59.7% |
Options analytics
Put / call volume
1.83
Put-heavy session
Put / call open interest
0.06
Positioning, not flow
Max pain
3.00
+1.4% from spot
ATM implied vol
124.2%
Nearest strike to spot
Skew (10% OTM)
-58.6%
Calls bid over puts
Call volume
29
Contracts, this expiry
Put volume
53
Contracts, this expiry
Heaviest call OI
3.00
2.26K contracts
Heaviest put OI
3.00
137 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.28 | -0.28 | -1.0% |
| Mar 2026 | -0.21 | — | — |
| Dec 2025 | -0.17 | -0.41 | -142.1% |
| Sep 2025 | -0.46 | 0.50 | +209.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.27 | 5 | $0 | 0.0% |
| Next quarter | -0.27 | 5 | $0 | 0.0% |
| Current year | -1.16 | 5 | $0 | 0.0% |
| Next year | -0.95 | 5 | $62.50K | 0.0% |
Analyst targets & ownership
Mean target$11.64
High target$16.00
Low target$6.00
Implied upside293.12%
Analyst count11
ConsensusNONE
Strong buy / Buy1 / 10
Hold0
Sell / Strong sell0 / 0
Held by insiders0.71%
Held by institutions75.39%
Institutions holding111
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
3.13
-5.36% from price
SMA 20
3.28
-9.83% from price
SMA 50
3.56
-16.75% from price
SMA 100
3.61
-18.01% from price
SMA 200
3.76
-21.30% from price
EMA 12
3.15
-5.97% from price
EMA 26
3.32
-10.75% from price
EMA 50
3.46
-14.39% from price
RSI (14)
31.4
Neutral
MACD (12,26,9)
-0.17
Hist -0.03
ATR (14)
0.19
6.41% of price
Realised vol 30D
36.5%
Annualised
Bollinger upper
3.65
20, 2σ
Bollinger lower
2.91
20, 2σ
50 / 200 cross
Death
3.56 vs 3.76
Trend bias
Below 200
-21.30%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.22
More volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
36.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-36.2%
Peak to trough
Max drawdown 5Y
-99.0%
Peak to trough
ATR 14
0.19
6.41% of price
Beta (reported)
0.58
5Y monthly, from filing
Short interest
Shares short
3.60M
Prior 4.63M
Change vs prior
-22.2%
Shorts covering
% of float
4.09%
Normal
% of shares out
3.96%
Against total outstanding
Days to cover
11.9
Crowded exit
Float
62.04M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 24, 26 | Barclays | INITIATED | — | Overweight |
| Jun 17, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Jun 15, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Jun 15, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 22, 26 | Citigroup | INITIATED | — | Buy |
| May 20, 26 | Jefferies | INITIATED | — | Buy |
| May 12, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 11, 26 | Rodman & Renshaw | MAINTAINED | Buy | Buy |
| Apr 2, 26 | Rodman & Renshaw | INITIATED | — | Buy |
| Mar 11, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Mar 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 7, 26 | UBS | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:10
Split dateJan 5, 2024
SEC filings
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-07
Corporate Changes & Voting Matters
8-K · 2026-06-18
Periodic Financial Reports
10-Q · 2026-05-12
Corporate Changes & Voting Matters
8-K · 2026-05-04
Corporate Changes & Voting Matters
8-K · 2026-04-22
Offering Registrations
S-8 · 2026-03-31
Corporate Changes & Voting Matters
8-K · 2026-03-19
Headlines
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
GlobeNewswire · 6d ago
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
GlobeNewswire · 15d ago
SAB BIO to Participate in Upcoming Investor Conferences
GlobeNewswire · 36d ago
SAB Biotherapeutics Q2 Earnings Call Highlights
MarketBeat · 61d ago
SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ...
GuruFocus.com · 62d ago
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
GlobeNewswire · 62d ago
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
GlobeNewswire · 69d ago
SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment
Insider Monkey · 84d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.